AF recurrence - search results
If you're not happy with the results, please do another search
Systematic review and meta-analysis finds P-wave duration to increase risk of AF recurrence after...
In their updated meta-analysis of 4,175 patients, Stergios Intzes together with a team from the Democritus University of Thrace, Alexandroupoli, Greece and the Heart...
EHRA 2022: Overweight patients at greater risk of AF recurrence
Overweight patients with atrial fibrillation (AF) are more likely to experience a return of the heart rhythm disorder after a corrective procedure than those...
AF Symposium 2022: Lower pulmonary vein to left atrium volume ratio predicts AF recurrence
Pulmonary vein-left atrial (PV/LA) volume ratio is a significantly better predictor power for atrial fibrillation (AF) recurrence than LA dimension in patients with normal...
CABANA pilot shows ablation more effective in preventing AF recurrence
Professor Douglas Packer presents the results of the pilot study at the American College of Cardiology Scientific Sessions.
Fitness linked to lower arrhythmia recurrence after AF ablation
Patients undergoing atrial fibrillation (AF) ablation, who are physically fit before the procedure, have a much higher chance of benefiting from the procedure and...
Lower rate of post-ablation arrhythmia recurrence found in patients with shorter AF episodes
Patients with atrial fibrillation (AF) episodes limited to less than 24 continuous hours had a significantly lower incidence of arrhythmia recurrence following AF ablation...
Arrhythmia mapping system improves freedom from AF during ablation
Vektor Medical has announced that use of the vMap arrhythmia mapping system during complex atrial fibrillation (AF) ablation was associated with significantly improved freedom...
Acesion announces positive phase two data from AF clinical trial
Acesion, the biotech developing first-in-class novel therapies for atrial fibrillation (AF), has today announced positive data from its phase two trial of AP30663, a...
ACC 2023: Pulsed AF trial yields “promising” safety and efficacy results for PFA system
Results of the Pulsed AF Pivotal trial, investigating pulsed field ablation (PFA) treatment in patients with paroxysmal and persistent atrial fibrillation (AF), have been...
AF Symposium hears late-breaking data from RFA and PFA trials
Biosense Webster has announced an update and late-breaking data from trials across radiofrequency ablation (RFA) and pulsed field ablation (PFA) at the 2023 AF...
Study reveals low reconnection rate with large antral lesion at PW after pentaspline PFA...
A first-of-its-kind analysis on electrophysiological findings in patients with recurrent atrial tachyarrhythmia (ATa) following pulmonary vein isolation (PVI) using the novel pentaspline pulsed-field ablation...
Ablation as first-line treatment cuts AF progression compared to antiarrhythmic drugs
Ablation as a first-line treatment for atrial fibrillation (AF) disease is associated with significantly better clinical outcomes than starting with antiarrhythmic drugs.
These were the...
Catheter ablation of AF “increased cerebral blood flow”, observational study finds
Catheter ablation of atrial fibrillation (AF) has favourable effects on cerebral blood flow, particularly in non-paroxysmal AF, research published in JACC: Clinical Electrophysiology.
The results...
AtriAN initiates second trial of pulsed field ablation in cardiothoracic surgery patients with paroxysmal...
AtriAN Medical has announced that it has completed enrolment of a second study using its selective pulsed field ablation (PFA) technology for the treatment...
Catheter ablation “economically attractive” compared to drug therapy for AF
Catheter ablation of atrial fibrillation (AF) was economically attractive compared with drug therapy in the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial...
AF Symposium 2022: Latest evidence for lattice tip catheter ablation strategies shared
Pulsed-field ablation (PFA) and/or radiofrequency ablation (RFA) using a lattice-tip catheter can both isolate pulmonary veins (PVs) and create linear lesions efficiently and safely,...
Same-day discharge for catheter ablation of atrial fibrillation deemed safe and feasible
A recent systematic review and meta-analysis, published in the Journal of Interventional Cardiac Electrophysiology, has deemed same-day discharge following catheter ablation of atrial fibrillation...
New data underpin drive towards earlier AF ablation strategies
Historically, catheter ablation has been reserved for atrial fibrillation (AF) patients who have failed to respond to, or tolerate antiarrhythmic drug therapy, electrophysiologist Dhiraj...
AtriAN Medical present results of Neural AF trial at AF Symposium 2022
According to a press release, AtriAN Medicals clinical data from the Neural atrial fibrillation (AF) study was presented by Vivek Reddy (Mount Sinai Hospital,...
Study shows safety and efficacy of robotic-guided ablation to treat paediatric arrhythmias
Stereotaxis has announced publication of a study in the International Journal of Cardiology: Heart & Vascular demonstrating superior safety and efficacy of Stereotaxis’ robotic...
Targeting atrial fibrosis in AF patients with low levels of disease “may help improve...
Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ablation success rates compared to PVI alone in patients with persistent...
ESC 2021: ACTIVE-AF finds benefits for exercise programme in AF patients
A six-month exercise programme helps maintain normal heart rhythm and reduces the severity of symptoms in patients with atrial fibrillation (AF), according to late-breaking...
Abbott initiates trial focusing on twin AF and heart failure treatments
Abbott has announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AF) and heart failure.
The TAP-CHF trial...
AF burden at six months predictive of hard clinical outcomes in heart failure
Atrial fibrillation (AF) burden at six months after catheter ablation is predictive of all-cause mortality and heart failure hospitalisation, in AF patients with heart...
AF Symposium 2021: Experts debate early ablation strategy in AF
The merits of catheter ablation as a first-line treatment for atrial fibrillation (AF) were considered during the second day of AF Symposium 2021 (29–31...
AF Symposium 2021: HARTCAP-AF supports hybrid over catheter ablation
Hybrid ablation, a procedure which involves “attacking” the atrial substrate from the epicardium and endocardium, has been shown to result in significantly higher freedom...
AF Symposium 2021: Studies explore lattice-tip catheter strategies for AF
Findings of two studies investigating the use of a lattice-tip catheter for the treatment of atrial fibrillation (AF) were presented during a late-breaking trial...
Regular alcohol consumption linked to increased AF risk
A study of nearly 108,000 people has found that people who regularly drink a modest amount of alcohol are at increased risk of atrial...
PRECAF study looks at elimination of distal coronary sinus to left atrial connection for...
Elimination of distal coronary sinus (CS) to left atrial (LA) connections reduced atrial arrhythmia recurrences compared to standard pulmonary vein (PV) isolation and non-PV...
ESC 2020 Congress: STOP AF First finds cryoballoon ablation safer than drug treatment for...
Cryoballoon catheter ablation as a first line treatment for paroxysmal atrial fibrillation (AF) was found to be safer and more effective than anti arrhythmic...
Prompt diagnosis “vital” in effective AF management
Dhiraj Gupta, consultant cardiologist and electrophysiologist at Liverpool Heart and Chest Hospital, (Liverpool, UK) discusses the current burden of atrial fibrillation (AF) on healthcare...
Contact force sensing catheters “safe and effective” in persistent AF ablation
Contact force (CF) sensing catheters have been shown to be safe and effective in persistent atrial fibrillation (AF) ablation, according to the findings of...
Results of PULSED AF trial presented at HRS 2020 Science
Initial results of the PULSED AF trial, the first-in-human results for paroxysmal or persistent atrial fibrillation (AF) treated with pulsed field ablation (PFA) were...
AF Symposium 2020: Myocardial specificity of pulsed field ablation provides safety advantage for persistent...
At the AF Symposium 2020 (23–25 January, Washington, DC, USA), Vivek Y Reddy (Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, USA)...
AF Symposium 2020: Use-as-needed NOAC strategy is safe and effective for selected AF patients
Speaking today at the AF Symposium (23–25 January, Washington, DC, USA), Francis Marchlinski (Hospital of the University of Pennsylvania, Philadelphia, USA) reported that selected...
ESC 2019: Catheter ablation may be up to 10 times more effective than drug...
Results from the Atrial fibrillation progression trial (ATTEST) were presented on 31 August at the European Society of Cardiology (ESC) Congress 2019 in Paris,...
Phased RFA for AF shows efficacy and quality of life improvements
Phased radiofrequency (RF) ablation using the PVAC GOLD catheter for pulmonary vein isolation in paroxysmal and persistent atrial fibrillation (AF) has demonstrated good outcomes for...
Biomarkers may predict AF after catheter ablation
Researchers have identified a combination of serum biomarkers that is independently associated with higher prevalence of atrial fibrillation, and with increased incidence and recurrence...
CABANA finds reduced AF and better quality of life after ablation but no reduction...
Catheter ablation for atrial fibrillation leads to a reduction in atrial fibrillation, better quality of life and lower hospitalisations than medical therapy, but does...
Thoracoscopic ablation and left atrial appendage excision found to be superior to catheter ablation...
Symptomatic atrial fibrillation (AF) patients with previous failed catheter ablation or structural changes associated with higher recurrence of AF could benefit from thoracoscopic ablation...
REAFFIRM: An interim analysis
The interim results of the REAFFIRM (Randomised Evaluation of Atrial Fibrillation treatment with Focal Impulse and Rotor Modulation guided procedures) trial showed there was...
Five surprising messages from this year’s Europe AF
1.
The "ILL-CONCEIVED" pallas study may be relaunched
John Camm
"I want to say just a few quick words about dronedarone", John Camm (St George's University of...
Have you considered this sleeping burden of atrial fibrillation (AF)?
This video has been sponsored by LivaNova.
AF is a growing epidemic affecting 33.5 million people today.1 Up to 91% of AF patients have co-morbidities.2 Among...
Repeat ablation with contact force sensing “does not necessarily guarantee a successful outcome” in...
Preliminary results from the ABLATOR observational registry have shown similar success rates (around 58%) in first time ablation and repeat ablation for persistent atrial...
First patients enrolled in Medtronic’s STOP AF First cryoballoon clinical trial
The first participants have been enrolled in Medtronic’s STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary...
Rate of early death after ventricular tachycardia ablation as high as 5%
Early post-procedural mortality occurred in 5% of cases of radiofrequency catheter ablation in patients with scar-related ventricular tachycardia (VT), with more than half of...
Pacemakers with Closed Loop Stimulation programming help to reduce recurrence of syncope
Patients with refractory reflex vasovagal syncope who received a pacemaker programmed with Closed Loop Stimulation (DDD-CLS, algorithm from Biotronik) had a seven-fold reduction in...
AF ablation associated with phrenic nerve injury: Is this complication now in our rear...
Phrenic nerve injury is a well-established complication of all types of atrial fibrillation (AF) ablation and is most common with balloon-based approaches, writes Hugh...
How innovation can unleash tremendous growth in the $3.4 billion AF ablation market
Shlomo Ben-Haim (London, UK), a professor of medicine and serial entrepreneur in the medical device industry, examines the drivers of expansion of the atrial...
Electrical left atrial appendage isolation helps to improve freedom from long-standing persistent AF
A randomised, multicentre study has found improvement in the long-term freedom from long-standing persistent atrial fibrillation (AF) in patients who underwent an ablation plus empirical electrical left atrial appendage isolation strategy. No major complications were reported.
Guideline-based algorithm helps to reduce syncope recurrence in old patients with severe syncopes
A sequential algorithm, which includes carotid sinus massage, tilt testing and implantable loop recorder implantation, helps to reduce syncope recurrence to 9% at one year in old patients with severe recurrent syncopes, according to results from the Syncope unit project 2 (SUP 2) study.
Botox reduces AF burden for up to a year after cardiac surgery
Botulinum toxin injected into epicardial fat pads during coronary artery bypass graft surgery reduced the incidence of postoperative atrial fibrillation compared with placebo, with substantial suppression persisting after one year, a pilot study has found.
HeartLight US pivotal study meets primary efficacy and safety endpoints
The trial, which randomised CardioFocus' HeartLight one-to-one versus the Biosense Webster Thermocool catheter, met both primary efficacy and safety endpoints and demonstrated a low learning curve for physicians.
Atrial fibrillation recurrence lower with sleep apnoea treatment
The use of continuous positive airway pressure was associated with a significant reduction in the recurrence of atrial fibrillation in patients with obstructive sleep apnoea, according to a new analysis of data.
Edoxaban approved for prevention of stroke and systemic embolism in non-valvular AF and treatment...
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and treatment of venous thromboembolism in deep vein thrombosis.
SMART-AF trial shows AF ablation with contact force sensing catheter is safe and effective
Results from the SMART-AF trial, recently published in the Journal of the American College of Cardiology, have shown that the ThermoCool SmartTouch contact force-sensing catheter is safe and effective for the treatment of drug-refractory symptomatic paroxysmal atrial fibrillation.
Population-based study confirms radiofrequency catheter ablation as safe and effective in paediatric patients
A new population-based study confirms previous study reports that radiofrequency catheter ablation is a safe method of arrhythmia treatment in children with long-term cumulative efficacy exceeding 90%, and a highly significant decrease in the procedure and fluoroscopy time during the study period.
TOCCASTAR trial meets primary safety and efficacy endpoints at Heart Rhythm 2014
Results from the first prospective, randomised study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.
EFFICAS I study yields new contact force guidelines in catheter ablation treatment of AF
Results from the EFFICAS I, a prospective multicentre study sponsored by Endosense, have led to the development of guidelines for target and minimum contact force, as well as minimum force time integral, during the catheter ablation treatment of paroxysmal atrial fibrillation.
Minimally invasive hybrid ablation is safe and effective for treatment for atrial fibrillation patients
One year after treatment completion, 80% of patients in normal sinus rhythm without administration of drugs, study says.
New HeartLight data reinforce single procedure chronic success rates in the treatment of AF
Results presented at the ESC congress showed that pulmonary vein isolation with the device led to a 99% acute success rate and up to an 82% chronic success rate at 12 months follow-up.
Intermittent rhythm monitoring fails to identify atrial fibrillation recurrence in a great proportion of...
Efstratios Charitos, Luebeck, Germany, and colleagues have reported in Circulation that two to four sessions of 24h intermittent rhythm monitoring has been shown to "under-detect atrial fibrillation recurrence and thus overestimate success rates of therapeutic interventions".
Pacemaker reduces syncope recurrence in patients with neurally mediated syncope
Results from the ISSUE 3 study show that active pacemaker therapy can reduce episodes of syncope in selected patients with severe asystolic neurally mediated syncope. Data were presented by Michele Brignole at the American College of Cardiology conference.
New consensus document for atrial fibrillation ablation previewed at Boston AF
Hugh Calkins, Maryland, USA gave a sneak preview of the forthcoming 2012 document on catheter ablation for atrial fibrillation. At Boston AF he said, the new document is not just a "brief update" of the previous HRS/EHRA/ECAS document, which was published in 2007, but a "comprehensive, state-of-the-art review of the field of catheter and surgical ablation for atrial fibrillation."
Gender does not affect periprocedural complications or long-term results of catheter ablation
Despite influencing the epidemiology, pathology, and clinical presentation of cardiac arrhythmias, gender does not appear to affect periprocedural complications and outcomes of catheter ablation, according to a study presented by Sonia Ammar, Munich, Germany at EHRA-Europace in Madrid, Spain.
Sanofi stops phase IIIb of trial using dronedarone in patients with permanent AF
The decision follows recommendations from the PALLAS trial's Operations Committee and the Data Monitoring Committee (DMC) which observed a significant increase in cardiovascular events in the dronedarone arm.
Repeat ablation procedures provide “acceptable” long-term relief for AF patients
Five-year follow-up results from a study of catheter ablation for atrial fibrillation shows long-term success increases when outcomes are measured after the last ablation procedure.
NICE guidance gives people living with AF more treatment options
Technology appraisal recommends the use of dronedarone in treating Atrial Fibrillation under specific conditions.
NICE publishes final draft guidance on dronedarone treating AF
Report suggests drug should only be considered as treatment option for people who have additional cardiovascular risks.
Trials beginning this year will compare AF ablation devices
An overview of clinical trials on AF ablation devices seeking FDA approval was presented by Hugh Calkins, Johns Hopkins Hospital, Baltimore, USA, at the Boston AF Symposium.
Paroxysmal and non-paroxysmal AF patients benefit from repeat catheter ablation
Isolation of the pulmonary vein antrum and the superior vena cava using intracardiac echocardiography and circular mapping can achieve encouraging cure rates.
XPECT: Monitoring AF with a minimally invasive device
John Camm, London, UK, analyses the first MRI approved insertable cardiac monitor (ICM) featuring an automatic AF detection algorithm.
Mayo Clinic receives US$48 million in grants to study catheter ablation for AF
The CABANA trial is designed to determine whether catheter ablation is more effective than drug therapy for the treatment of atrial fibrillation.
Advances in ablation of long-standing persistent AF
Matthew Wright, Hopital Cardiologique du Haut-Levaque, Bordeaux-Pessac, France talks about techniques and developments in catheter ablation for persistent AF.
Novel imaging technique may predict outcomes in AF patients
Researchers have found that delayed-enhancement magnetic resonance imaging holds promise for predicting treatment outcomes and measuring disease progression.
Novel imaging approach may assist in predicting success of treatment for AF
University of Utah researchers have developed a magnetic resonance imaging-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation.
New imaging approach may assist in predicting success of treatment for AF
University of Utah researchers have developed a magnetic resonance imaging-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation.
Cryoablation appears effective for paroxysmal but not persistent AF
The novel cryoballoon device (Arctic Front, Cryocath) appears safe and effective for patients with paroxysmal atrial fibrillation (AF), but not for those with persistent AF, according to German researchers.
ATHENA data suggest decrease in stroke risk with dronedarone for AF
Results from a post-hoc analysis of the data from the ATHENA trial show that dronedarone reduces stroke risk in patients with atrial fibrillation.
Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results
An international multicentre registry evaluating the role of remote robotic navigation and contact force sensing in persistent atrial fibrillation (AF) treatment has found that, at one year, a higher proportion of patients treated with this modality were free from AF recurrences with a single procedure as compared with both manual/contact force sensing and robotic/no contact force sensing procedures.
AHA scientific statement offers insight into sleep-disordered breathing and its link to arrhythmia
A new scientific statement from the American Heart Association (AHA) provides guidance about sleep-disordered breathing and its association with the development of cardiac arrhythmia.
Published...
Single-shot pulsed-field ablation yields “excellent” PVI durability
Pulmonary vein isolation (PVI) with a “single-shot” pulsed-field ablation (PFA) catheter results in excellent PVI durability and acceptable safety with a low one-year rate...
High power CLOSE-guided PVI “increases procedural efficiency”
Results of a prospective randomised evaluation of using high power during CLOSE-guided pulmonary vein isolation (PVI) using the Thermocool Smarttouch (Biosense Webster) device—the POWER-AF...
US FDA approves Biosense Webster’s Thermocool Smarttouch SF ablation catheter
Johnson & Johnson Medical Devices Companies has announced the US Food and Drug Administration (FDA) approval of Biosense Webster’s Thermocool Smarttouch SF ablation catheter...
Is CABANA a positive or negative trial?
Several treatment options are available for atrial fibrillation (AF), including pharmacological rate or rhythm control, and catheter or surgical ablation. However, consensus as to...
Nassir Marrouche
Nassir Marrouche is a prominent electrophysiologist, executive director of the Comprehensive Arrhythmia Research and Management (CARMA) Centre at the University of Utah in Salt...
Superior vena cava does not seem to contribute to long-standing persistent atrial fibrillation
The arrhythmogenicity of the superior vena cava has been rarely detected in patients with long-standing persistent atrial fibrillation, according to study from China recently...
Fluoroscopy times and radiation dose reduced in atrial fibrillation ablation with contact force-sensing technology
A real-world study has found that the SmartTouch (Biosense Webster) contact force-sensing catheter coupled with an Advanced Catheter Location feature during atrial fibrillation (AF) ablation reduced fluoroscopy times by 77%, radiation dose by 71% and procedural time by 19%.
High-dose visually guided laser ablation superior to low-dose ablation in treatment of patients with...
New data have shown that acute pulmonary vein isolation was achieved after a single visually guided circular lesion set in 89% and 69% of patients in the high and low-dose groups, respectively.
Study looks at efficacy of AI-based EGM analysis tool
Volta Medical has announced that peer-reviewed results from the company’s Ev-AIFib proof of concept study with its VX1 decision support software has been published...
Centauri pulsed electric field system gains CE mark approval
Galaxy Medical has announced that it received the CE mark for its Centauri pulsed electric field (PEF) system and launched its commercial programme.
The approval...
HRS 2022: Registry data support role of cardioneural ablation to address vasovagal syncope
Findings of the US multicentre cardioneural ablation (CNA) registry were presented during a late-breaking clinical trial session at the Heart Rhythm Society’s 2022 annual...
Q-FFICIENCY trial shows promise for temperature-controlled ablation
Use of temperature-controlled ablation for the treatment of atrial fibrillation (AF) is effective and highly efficient, according to Jose Osorio—the director of electrophysiology at...
HRS 2021: Early VT catheter ablation beats medical therapy in patients at risk for...
Results of the PAUSE-SCD trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalisation, and death when catheter ablation is...
Expanded FDA approval for Medtronic’s Arctic Front cryoablation catheter
Medtronic has received US Food and Drug Administration (FDA) expanded approval for the Arctic Front family of cardiac cryoablation catheters for the treatment of...
RHYTHM AI announces latest publication of data backing its STAR Mapping system
RHYTHM AI has announced publication of a clinical outcome study for its STAR (Stochastic Trajectory Analysis of Ranked signals) Mapping system, which is designed...
AHA 2020: Medtronic shares results of cryoablation studies
Medtronic has announced the presentation of results of three studies which it says demonstrate that cryoablation is superior to drug therapy for first-line treatment...
Paper highlights use of robotic system for catheter ablation in COVID-19 patients
Stereotaxis has announced the publication of a paper in the European Heart Journal highlighting the benefits of using robotic technology for the management of...
HRS 2020 Science: Packer assesses CABANA’s legacy
As part of this year’s HRS 2020 Science virtual event Douglas L Packer (Mayo Clinic, Rochester, USA) delivered the 2020 Eric N Prystowsky lecture...
Virtual ACC: Ethanol infusion in vein of Marshall improves catheter ablation outcomes
The infusion of ethanol via the vein of Marshall (VOM), coupled with catheter ablation, leads to improved outcomes for patients with persistent atrial ablation, according to the findings of a study presented by...
Leading electrophysiologists identify four key studies that will shape arrhythmia treatment in 2020
Leading electrophysiologists have pinpointed four clinical studies due to report findings in 2020—AMULET IDE, aMAZE IDE, PULSED AF and CEASE AF—that they expect to...
Tackling focal VT may improve catheter ablation in structural heart disease
Uncovering and abolishing focal ventricular tachycardia (VT) may further improve outcomes of catheter ablation in the treatment of structural heart disease, a study published...
WRAP-IT shows significant mortality risk with CIED infection and reduced quality of life
Major infection in patients with cardiac implantable electronic devices (CIED) is associated with a threefold risk of mortality at one year, and impaired quality...
Biosense Webster launches initiatives to tackle atrial fibrillation
Biosense Webster, a Division of Johnson & Johnson, has reaffirmed its commitment to tackling atrial fibrillation (AF) by launching two major initiatives to coincide...
Randomised controlled trial finds that efficacy is not compromised by using a shorter cryoapplication...
In a late-breaking session at the European Heart Rhythm Association annual congress (EHRA; 17–19 March, Lisbon, Portugal), Jason Andrade of Vancouver, Canada presented the...
Atrial fibrillation related to PFO closure occurs early and is transient
A new meta-analysis of patients undergoing percutaneous closure of patent foramen ovale (PFO) after cryptogenic shock supports previous studies that indicate PFO closure is...
Study shows improved quality of life and reduced symptoms in patients treated with Cryoballoon
New findings from the CRYO4PERSISTENT AF clinical trial demonstrate improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions...
Autonomic modulation for refractory ventricular arrhythmias: Going beyond the heart
Patients with scar-related ventricular tachycardia (VT) do not often achieve a cure. Jason S Bradfield and Kalyanam Shivkumar write in Cardiac Rhythm News about...
CABANA trial provides important new data on clinical and quality of life effects of...
Catheter ablation for atrial fibrillation (AF) produced no significant improvement in death, disabling stroke, serious bleeding, or cardiac arrest but did reduce death or...
Ultralow temperature ablation: Results from the Cryocure I and Cryocure II trials
The trials found that ultralow temperature cryoablation is feasible and shows excellent safety and efficacy. The clinical outcomes for flutter ablation show a 94%...
Real-time lesion formation and gap detection during ablation: DURABLE-I follow-up
One-year results from the Dielectric Unravveling of RAdiofrequency ABLation Effectiveness (DURABLE-I) clinical trial have shown that the KODEX (Navix International Limited) system help to...
US Patent Office allows AblaCor five ablation catheter-anchoring patents
AblaCor medical corporation has announced that it has received a notice of allowance from the United States Patent & Trademark Office on five additional patents for...
Biomarker predicts success of atrial fibrillation treatment
Written by Hannah Woolley, Cardiac Rhythm News Editor
Heart imaging has been successfully used to predict the benefit or futility of catheter ablation. The investigators...
Noninvasive radioablation: Radiotherapy shows 99.9% VT burden reduction
A small study by Phillip S Cuculich (Washington University School of Medicine, St Louis, USA) et al has shown that radiation therapy, commonly used...
Imricor announces new developments in MR compatible ablation products
Imricor is developing a magnetic resonance (MR) compatible injection catheter and has announced a joint development agreement with MiRTLE Medical to integrate MiRTLE’s MR...
Update on treatment strategies for vasovagal syncope
When speaking on therapy of vasovagal syncope (VVS), it is important to stress that a specific treatment of VVS is only rarely necessary in...
Cardiac sympathetic denervation helps to reduce sustained ventricular tachycardia and ICD shocks
By Angela Gonzalez
A retrospective study, including the largest series of patients with refractory ventricular tachycardia undergoing cardiac sympathetic denervation for structural heart disease, has...
ACC 2017: Anticoagulant treatment may be unnecessary for stroke prevention following ablation for atrial...
For patients with persistent atrial fibrillation or those who are at high risk for recurring atrial fibrillation, catheter ablation is recommended, followed most often...
New multidisciplinary care pathway helps to reduce the risk of recurrent stroke in cryptogenic...
A growing body of evidence suggests that the underlying cause for many cryptogenic strokes is atrial fibrillation (AF). However, many of these patients do...
Advances in non-invasive imaging to treat ventricular tachycardia and prevent sudden cardiac death
We are standing at a crossroads of non-invasive imaging technologies in the field of electrophysiology. Advances in cardiac magnetic resonance imaging (CMRI) mean that...
Health Canada approves edoxaban for two indications
Health Canada has approved edoxaban (Lixiana, Servier Canada) for the prevention of stroke and for systemic embolic events in patients with non-valvular atrial fibrillation,...
ESC and EACTS launch first collaborative atrial fibrillation guidelines
The first European Society of Cardiology (ESC) Guidelines on Atrial Fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) have been...
The OASIS trial: A critical appraisal
Recent results of the first randomised trial—OASIS trial—to compare rotor-only ablation with two other ablation strategies in non-paroxysmal atrial fibrillation patients found poor outcomes...
Relevance of imaging for ventricular tachycardia ablation
Cardiac imaging has emerged as an integral part of mapping and ablation in a variety of complex arrhythmias. Advances in imaging techniques, especially the...
Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study
Pre-clinical data, presented at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy (IDSS; 6–9 March, Tel Aviv, Israel),...
Catheter ablation is superior to amiodarone in the treatment of patients with heart failure...
New research indicates that catheter ablation may achieve greater long-term freedom from atrial fibrillation, as well as a reduction in unplanned hospitalisation and mortality...
Importance of obstructive sleep apnoea in EP
Syed Rafay A Sabzwari and Dhanunjaya Lakkireddy (Kansas City, USA) review the importance of obstructive sleep apnoea (OSA) in electrophysiology and cardiology at large,...
Radiofrequency catheter ablation shows benefits for recurrent ventricular tachycardia patients
A prospective, multicentre study—THERMOCOOL VT—analysing a cohort of non-randomised patients, published in February in the Journal of the American College of Cardiology, has shown...
Ventricular tachycardia ablation in Chagas disease
Guilherme Fenelon (Sao Paulo, Brazil) overviews the role of ablation of ventricular tachycardia in Chagas disease. He says: catheter ablation in Chagas disease remains...
First randomised trial shows “poor outcomes” with rotor ablation
OASIS, the first randomised, controlled, multicentre clinical trial to compare rotor-only ablation with two other ablation strategies in non-paroxysmal atrial fibrillation patients found “poor...
Ablation should be “preferred approach” in drug-resistant ventricular tachycardia
A multicentre, randomised controlled trial has shown that catheter ablation is superior to intensified antiarrhythmic drug therapy in reducing death, appropriate implantable cardioverter defibrillator...
Routine ganglionic plexus ablation “should not be performed” in advanced atrial fibrillation patients
Results from the AFACT trial have shown no clinical benefits and significantly more complications associated with routine ganglionic plexus ablation for advanced atrial fibrillation patients. Data were presented at the 37th Heart Rhythm Society Scientific Sessions (HRS; 4-7 May, San Francisco, USA).
HeartLight System gets FDA approval for atrial fibrillation treatment
CardioFocus has announced that it has received premarket approval from the US Food and Drug Administration (FDA) for its HeartLight Endoscopic Ablation System for the treatment of patients with paroxysmal atrial fibrillation.
Hybrid and surgical atrial fibrillation ablation: Opportunity, threat or both?
Despite major advances in techniques and technology over the past 15 years, the clinical outcomes for catheter ablation in non-paroxysmal atrial fibrillation patients remain...
Stereotaxis begins multicentre, randomised superiority study on ventricular tachycardia ablation outcomes
Stereotaxis has initiated its first prospective, multicentre, randomised clinical study to compare radiofrequency ablation outcomes generated using its Niobe ES remote magnetic navigation system to manual approaches in ischaemic scar ventricular tachycardia (VT) patients.
LuxCath technology demonstrates promising results during first-in-man cardiac ablation procedures
The LuxCath optical tissue interrogation technology was used in eleven patients suffering from arrhythmias such as atrial flutter, AV nodal re-entrant tachycardia, and atrial fibrillation.
Greater long-term success rates for Stereotaxis’ Niobe system compared to manual catheter
The results of an independent, multicentre study, which looked at the procedural benefits and outcomes of patients undergoing radio frequency ablation therapy for ventricular tachycardia, were published at the AHA.
CardioFocus’ HeartLight PMA for the treatment of atrial fibrillation filed and accepted for review...
The accepted PMA application includes safety and effectiveness data from the company's multicentre HeartLight pivotal clinical trial, a randomised, controlled study in which a total of 353 patients were treated at 19 US centres.
Study highlights advantages of Stereotaxis platform in treating ventricular tachycardia
A seven-year study indicates the Stereotaxis remote magnetic navigation platform's success in ventricular tachycardia ablations compared to both contact force sensing and other manual catheters.
Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson
Michael Glikson (director of Davidai Arrhythmia Center, Heart Center, Sheba Medical Center, Tel Hashomer, Israel), vice-chairperson scientific programme for EHRA EUROPACE-CARDIOSTIM 2015, talks to Cardiac Rhythm News about the highlights of this years' congress.
FDA approves trial to evaluate Lariat ligation of the left atrial appendage as a...
The randomised, controlled AMAZE trial, will evaluate the use of the Lariat device for the ligation of the left atrial appendage as an adjunctive treatment to ablation in patients with persistent or long-standing persistent atrial fibrillation.
First-in-human study backs neuromodulation to treat paroxysmal atrial fibrillation
A first-in-human study shows low level transcutaneous electrical vagus nerve stimulation, a completely non-invasive approach, suppresses paroxysmal atrial fibrillation.
Catheter ablation superior to amiodarone for patients with persistent atrial fibrillation and heart failure
Speaking at the 2015 American College of Cardiology Annual Scientific Session, Luigi Di Biase reported that-compared with the antiarrhythmic drug amiodarone-catheter ablation significantly increases the rate of freedom of recurrence in patients with persistent atrial fibrillation and heart failure.
FDA approves Savaysa for reduction of stroke risk in non-valvular atrial fibrillation and for...
Savaysa (edoxaban) is an oral, once-daily selective factor Xa inhibitor, designed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
St. Jude Medical begins study of ablation procedures to treat ventricular tachycardia
The FlexAbility ablation catheter will be used to assess benefits of catheter ablation as an adjunctive therapy for patients at risk for life-threatening arrhythmias.
Ventricular tachycardia treatment with robotic catheter ablation shows positive results
A study undertaken in the UK has shown that radiofrequency ablation of scar-related ventricular tachycardia, using robotic navigation, is safe and feasible and has resulted in 95% reduction in total implantable cardioverter defibrillator (ICD) therapy burden at six months.
FDA makes recommendation on Daiichi Sankyo’s Savaysa
Daiichi Sankyo has announced that the FDA has recommended approval of once-daily Savaysa (edoxaban) 60mg dosing regimen.
St Jude Medical receives FDA approval of TactiCath Quartz Contact Force Ablation Catheter
St Jude Medical has announced the US Food and Drug Administration (FDA) approval of its TactiCath Quartz irrigated ablation catheter, the company's newest technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure.
John Muir Health’s Concord medical centre one of 20 hospitals in USA to use...
John Muir Health's Concord medical centre is one of just 20 hospitals in the USA to begin treating patients who suffer from atrial fibrillation with a new procedure that features the FDA-cleared FIRMap catheter.
Novel oral anticoagulants an option for patients with atrial fibrillation
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
Substrate based ablation superior than conventional ablation of stable clinical ventricular tachycardia
For stable clinical ventricular tachycardias, a substrate based ablation approach is more effective than conventional ablation preventing recurrences from any ventricular tachycardias in patients with ischaemic cardiomyopathy, according to results of the VISTA study, which is the first randomised trial performed in this area.
St Jude Medical presents comprehensive clinical evidence during Heart Rhythm 2014
Clinical evidence about the company's cardiac rhythm management and ablation technologies will be provided in 38 sessions, including three late-breaking clinical trial sessions.
Detection of atrial fibrillation with insertable cardiac monitors is superior to standard monitoring in...
Results from the CRYSTAL AF trial have shown that atrial fibrillation in patients with cryptogenic stroke is better detected with insertable cardiac monitors than standard monitoring at six, 12 and 36 months.
New data support use of Zio Patch to identify cardiac arrhythmias in stroke and...
New study data support the use of the Zio Patch to help identify underlying cardiac arrhythmias in patients who have had a stroke or transient ischaemic attack. The Zio Patch enables long-term continuous monitoring to detect sporadic heart rhythm disturbances, including atrial fibrillation.
Antonio Raviele
Antonio Raviele (Venice, Italy), cofounder of the VeniceArrhythmias congress, implanted the first intravenous defibrillator lead in Italy. He spoke to Cardiac Rhythm News about this experience, his current research, his projects dedicated to enhance awareness on cardiac arrhythmias and the highlights of VeniceArrhythmias 2013
Delayed enhancement-MRI detected atrial fibrosis could predict successful ablation in atrial fibrillation
Atrial fibrosis detected using delayed enhancement magnetic resonance imaging (DE-MRI) seems to be an independent predictor of procedural outcome in patients undergoing ablation of atrial fibrillation, according to results of the DECAAF (Delayed enhancement-MRI determinant of successful catheter ablation of atrial fibrillation) study
St Jude Medical acquires Endosense
St Jude Medical has announced the acquisition of Endosense. The acquisition adds to the company's electrophysiology portfolio. St Jude Medical has made an initial payment of approximately 159 million Swiss Francs (US$170 million) and acquired 100% of the outstanding equity of Endosense.
Complete pulmonary vein isolation more effective in atrial fibrillation treatment
Complete linear lesions when using catether ablation to isolate pulmonary veins have been shown to be more effective than incomplete lesions in preventing recurrence of atrial fibrillation, according to results from the GAP-AF study presented at a late-breaking trial session of the European Heart Rhythm Association (EHRA) Europace meeting (23-26 June, Athens, Greece).
Ablation superior to medical therapy for patients with persistent atrial fibrillation
According to results from the SARA study, presented at a late-breaking trial session of the European Heart Rhythm Association (EHRA) Europace meeting (23-26 June, Athens, Greece), catheter ablation therapy has been shown to be superior to medical therapy for maintenance of sinus rhythm in patients with persistent atrial fibrillation.
Researchers find a new possible cause of sudden infant death
Researchers in USA and Australia have found a new potentially treatable cause of sudden infant death, consisting of idiopathic ventricular fibrillation preceded by ST segment changes and QRS widening.
Renal denervation now under consideration for arrhythmias
Studies are exploring renal denervation as an adjunctive treatment in other diseases characterised by sympathetic overactivity such as ventricular arrhythmias, atrial fibrillation, metabolic syndrome and obstructive sleep apnoea. Cardiac Rhythm News spoke to leading physicians who are investigating this technology for the management of atrial fibrillation.
Atrial fibrillation may be reduced in sleep apnoea patients using airway pressure therapy and...
Continuous positive airway pressure may help to reduce atrial fibrillation recurrence in patients with obstructive sleep apnoea undergoing pulmonary vein isolation, a study published ahead of print in the Journal of the American College of Cardiology (JACC) has found.
Syncope events in bifascicular block patients can be reduced with permanent dual chamber pacing,...
Massimo Santini, Rome, Italy, and others have recently published results from the PRESS study. They found that by using a dual chamber pacemaker programmed to 60ppm lower rate the number of syncope events can be reduced in bifascicular block patients.
HeartLight Endoscopic Ablation System to be highlighted at Frankfurt Atrial Fibrillation Academy 2013
The Annual Frankfurt Atrial Fibrillation Academy Symposium will highlight the latest innovations and research in atrial fibrillation therapy.
CardioFocus HeartLight US pivotal trial on track for full enrolment in 2013
The HeartLight pivotal trial is randomising the HeartLight system against the ThermoCool Catheter, and will randomise an estimated 350 patients in the multicentre US trial.
Successful catheter ablation may reduce total mortality
A study recently published in EP Europace has shown that successful catheter ablation of atrial fibrillation may reduce the risk of total mortality, cardiovascular mortality and total vascular events in patients with an increased risk of stroke.
HeartLight Ablation System receives unique classification code in Germany for the treatment of atrial...
Use of the new code allows the German Institute of Medical Documentation and Information to track the number of atrial fibrillation patients being treated with laser ablation guided by endovascular endoscopy and provides the initial step to receiving a specific diagnosis-related group code for the procedure.
Are infants with supraventricular tachycardia being over treated?
A study by Shubbhayan Sanatani, Vancouver, Canada, and colleagues has shown that infants (aged 0-1 year) with supraventricular tachycardia who receive medical prophylaxis do not have a first recurrence after six months of age-suggesting that the current approach of treating patients for the first year of life is too long.
“Clear gap” between guidelines and clinical practice
Elena Arbelo, Barcelona, Spain, presented one-year results from the first European study of real-life epidemiology of catheter ablation for atrial fibrillation. At the ESC annual meeting, Arbelo said: "There is a clear gap between recommendations and actual clinical practice."
Global and inferior J wave amplitudes associated with recurrent ventricular fibrillation
According to a study presented by Laurent Roten, Bordeaux, France, at Cardiostim, in patients with early repolarisation and who had survived a sudden cardiac arrest, global and inferior J wave amplitudes were significantly higher in patients with recurrent ventricular fibrillation than in the remaining patients.
Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment
Short-term antiarrhythmic drug treatment after cardioversion is nearly as effective in preventing recurrences of atrial fibrillation as long-term treatment, data from Flec-SL show.
Catheter ablation of ventricular tachycardia in patients with ARVD/C significantly reduces the burden of...
A new study, published in Circulation: Arrhythmia and Electrophysiology, indicates that catheter ablation of ventricular tachycardia is an important treatment option in patients with ARVD/C, despite a high rate of ventricular tachycardia recurrence, because it reduces the burden of the arrhythmia
Hugh Calkins
Hugh Calkins, chair of the upcoming Heart Rhythm 2012─Scientific Sessions Program Committee, spoke to Cardiac Rhythm News about his career highlights, Heart Rhythm 2012, and the new consensus document on catheter and surgical ablation of atrial fibrillation.
New study to investigate the role of early radiofrequency ablation in delaying progression of...
ATTEST, a prospective, multicentre, randomised, controlled study will compare pulmonary vein isolation (using Biosense Webster's ThermoCool catheters and the company's Carto 3 or Carto XP mapping systems) with drug therapy (rate or rhythm control) in patients with paroxysmal atrial fibrillation.
Paroxysmal atrial fibrillation may account for some unexplained strokes
Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
Single atrial fibrillation ablation procedure achieves high pulmonary vein isolation rates, study shows
Researchers in Germany achieve 98% acute pulmonary vein isolation, with 77% of patients in sinus rhythm at approximately nine months follow-up.
Measuring both left atrial size and the amount of left atrial fibrosis may improve...
A study, published in Heart, indicates that the combined assessment of left atrial size and the amount of left atrial fibrosis may improve the identification of patients who have a high likelihood of successful ablation.
Remote magnetic navigation and ablation shows promise in patients with scar-related ventricular tachycardia
"The main advantage of the Niobe Remote Magnetic Navigation System (Stereotaxis), is the precise mapping and identification of the critical diseased portions of the heart that allows physicians to perform ablation in a more effective way," said Petr Neuzil, lead investigator of the STOP-VT study presented at the ESC Congress in Paris.
ESC announces review on atrial fibrillation guidelines
Following the early termination of the PALLAS trial, the Guidelines Department of the European Society of Cardiology (ESC) has issued a new statement with regards to the use of dronedarone in atrial fibrillation patients, in accordance with advice given by the European Medicines Agency and the US Food and Drug Administration.
Dutch experience deems totally subcutaneous ICD “viable alternative”
The subcutaneous implantable cardiac defibrillator (S-ICD) system is a viable alternative to conventional ICD systems for selected patients, results from a Dutch experience have shown.
Reveal insertable cardiac monitor led to effective diagnosis and specific treatment for patients with...
Medtronic's PICTURE registry results show that device led to diagnosis and treatment for 78% of patients who experience a recurrent syncopal event.
Multaq receives positive recommendation by NICE in new appraisal consultation document
The NICE appraisal committee's preliminary recommendation is to endorse Multaq as a first choice therapeutic option after beta-blockers for non-permanent AF patients.
Dronedarone approved in the European Union for patients with atrial fibrillation
Multaq, developed by Sanofi-aventis, is the first new anti-arrhythmic drug to be approved in Europe in the last 10 years.
Analysis of ATHENA shows stroke reduction with dronedarone
Patients receiving dronedarone for atrial fibrillation on top of adequate antithrombotic medication presented a significantly lower incidence of stroke, according to Stefan Hohnloser.
Dronedarone recommended for approval in the European Union
The European Medicines Agency has adopted a positive opinion recommending the grant of a marketing authorisation for Multaq (dronedarone, 400mg tablets).
Robotic vs. magnetic navigation
Drs Andrea Natale and Carlo Pappone debate the merits of magnetic (Stereotaxis) or robotic (Hansen Medical) navigation for catheter ablation of atrial fibrillation.
Stanley Nattel
Stanley Nattel, Montreal, Canada, spoke to Cardiac Rhythm News about his career, the challenges facing electrophysiology, and the future of the research on drugs for arrhythmias.
